Fig 1: (A) Schematic showing the sphingolipid metabolic pathway where serine palmitoyl transferase (SPT1–2), 3–Ketosphinganine reductase (KDSR), Dihydroceramide desaturase (DEGS1–2), Ceramide synthases (CERS1–6), Ceramide transferase (CERT), Ceramide 1-phosphate phosphatase (C1PP), N–Acylsphingosine amidohydrolase (ASAH1, ASAH2), Alkaline ceramidase (ACER1, ACER3), Sphingosine–1–phosphate kinase (SPHK1, 2), Sphingosine–1–phosphate phosphatase (S1PP), Sphingosine–1–phosphate lyase (S1PL), Ceramide Kinase (CERK), Sphingomyelin Phosphodiesterase (SMPD1–4), Sphingomyelin synthase (SMS1–2), UDP-Glucose ceramide glucosyltransferase (UGCG), ß–glucocerebrosidase (GBA1), ß–galactosidase (GLB1), ß–1,4–Galactosyltransferase 6 (B4GALT6) are the enzymes of the pathway. (B) Schematic showing major subtypes of breast cancer, such as luminal A, luminal B, luminal B with HER2 overexpression (also called triple-positive, TPBC), triple-negative (TNBC)/Basal-like, and HER2+.
Supplier Page from MilliporeSigma for Anti-ASAH1 antibody produced in rabbit